Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 2/20 | 0.52 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | CD38 | P28907 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4246679 | 0.89 | PDE7A (0.44) | PDE7AMAP4K4PDE4DCD38 | |
| SCHEMBL6453740 | 0.85 | PDE7A (0.38) | PDE7ACD38NPC1RAB9AADORA3 | |
| SCHEMBL6450379 | 0.79 | IP6K1 (0.39) | PDE7ANPC1RAB9AADORA3ADORA2A | |
| SCHEMBL6454854 | 0.78 | NPC1 (0.48) | PDE7APDE4DNPC1RAB9ANUDT1 | |
| SCHEMBL6464643 | 0.71 | RAB9A (0.52) | NPC1RAB9ALMNASMN1; SMN2TDP1 | |
| SCHEMBL4250347 | 0.69 | PDE7A (1.00) | PDE7APDE4D | |
| SCHEMBL4250343 | 0.69 | PDE7A (1.00) | PDE7APDE4D | |
| SCHEMBL4250476 | 0.68 | PDE7A (0.50) | PDE7APDE4DNPC1RAB9ALMNA | |
| SCHEMBL4250308 | 0.65 | PDE7A (0.69) | PDE7AMAP4K4PDE4D | |
| SCHEMBL4250314 | 0.65 | PDE7A (0.69) | PDE7AMAP4K4PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1492778-A1 | (4,2-DISUBSTITUTED-THIAZOL-5-YL)AMINE COMPOUNDS AS PDE7 INHIBITORS | Warner-Lambert Company LLC (US) | 2005-01-05 | — | — | EP | claimed |
| US-6753340-B2 | AUTOIMMUNE DISEASE, ANTIARTHRITIC AGENTS, ANTIALLERGENS, ANTICANCER AGENTS | WARNER-LAMBERT COMPANY LLC | 2004-06-22 | — | — | US | claimed |
| US-20030191167-A1 | (4,2-Disubstituted-thiazol-5-yl)amine compounds as PDE7 inhibitors | WARNER-LAMBERT COMPANY LLC | 2003-10-09 | — | — | US | claimed |
| WO-2003082839-A1 | (4,2-DISUBSTITUTED-THIAZOL-5-YL)AMINE COMPOUNDS AS PDE7 INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2003-10-09 | — | — | WO | claimed |
| EP-1348701-A1 | (2,4-disubstituted-thiazol-5-yl) amine compounds as PDE7 inhibitors | Warner-Lambert Company LLC (US) | 2003-10-01 | — | — | EP | claimed |
| US-20090111837-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF NEUROPATHIC PAIN | PFIZER INC. | 2009-04-30 | — | — | US | disclosed |
| EP-1855686-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF NEUROPATHIC PAIN | Pfizer Limited (GB) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006092691-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF NEUROPATHIC PAIN | PFIZER LIMITED (GB) | 2006-09-08 | — | — | WO | disclosed |
| EP-1492778-A1 | (4,2-DISUBSTITUTED-THIAZOL-5-YL)AMINE COMPOUNDS AS PDE7 INHIBITORS | Warner-Lambert Company LLC (US) | 2005-01-05 | — | — | EP | disclosed |
| US-6753340-B2 | AUTOIMMUNE DISEASE, ANTIARTHRITIC AGENTS, ANTIALLERGENS, ANTICANCER AGENTS | WARNER-LAMBERT COMPANY LLC | 2004-06-22 | — | — | US | disclosed |
| US-20030191167-A1 | (4,2-Disubstituted-thiazol-5-yl)amine compounds as PDE7 inhibitors | WARNER-LAMBERT COMPANY LLC | 2003-10-09 | — | — | US | disclosed |
| WO-2003082839-A1 | (4,2-DISUBSTITUTED-THIAZOL-5-YL)AMINE COMPOUNDS AS PDE7 INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2003-10-09 | — | — | WO | disclosed |
| EP-1348701-A1 | (2,4-disubstituted-thiazol-5-yl) amine compounds as PDE7 inhibitors | Warner-Lambert Company LLC (US) | 2003-10-01 | — | — | EP | disclosed |
| EP-1348701-A1 | (2,4-disubstituted-thiazol-5-yl) amine compounds as PDE7 inhibitors | Warner-Lambert Company LLC (US) | 2003-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191167-A1 | (4,2-Disubstituted-thiazol-5-yl)amine compounds as PDE7 inhibitors | PDE7A, PDE9A, PDE3A | PDE7A 1/4885MAP4K4 1730/4885PDE4D 18/4885 |
| US-20090111837-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF NEUROPATHIC PAIN | PDE7A, PDE7B, PDE3A | PDE7A 1/4885MAP4K4 1680/4885PDE4D 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.